Session 2 graf_von_der_schulenburg
-
Upload
eurordis-rare-diseases-europe -
Category
Documents
-
view
190 -
download
0
Transcript of Session 2 graf_von_der_schulenburg
![Page 1: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/1.jpg)
The German Plan for Rare Diseases: A Development in Progress
J.-Matthias Graf von der Schulenburg
Krakow, 14 May 2010
![Page 2: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/2.jpg)
Three questions
What is the issue?
What do we know?
What has to be done?
2© Prof. Dr. J.-M. Graf von der Schulenburg
![Page 3: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/3.jpg)
Three questions
3© Prof. Dr. J.-M. Graf von der Schulenburg
What is the issue?
What do we know?
What has to be done?
![Page 4: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/4.jpg)
4© Prof. Dr. J.-M. Graf von der Schulenburg
AllocationEfficiency
StabilizationCost stability and continuity of the system
DistributionFair allocation
Facts Appraisements
Why do we need health service research? Dimensions of an economic
evaluation…
![Page 5: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/5.jpg)
Three questions
5© Prof. Dr. J.-M. Graf von der Schulenburg
“Are we actually moving in a circular course, Olaf?”
What is the issue?
What do we know?
What has to be done?
![Page 6: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/6.jpg)
6© Prof. Dr. J.-M. Graf von der Schulenburg
Altogether only insufficient scientific knowledge (studies,
publications etc.) about the life situation, the quality and the range of care for people with Rare Diseases in the German
health care system
![Page 7: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/7.jpg)
How do we proceed?
BMG-study• Literature research• Discussions with experts and persons concerned• Discussions with focus groups• Wide survey with a questionnaire
Specific evaluation depending on an indication (CF-study)
EU-study• Social Economic Burden and Health-Related Quality of Life in Patients
with Rare Diseases in Europe (BURQOL-RD)• Coordinator: Prof. Bastida / Spain
7© Prof. Dr. J.-M. Graf von der Schulenburg
![Page 8: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/8.jpg)
Which perspectives were taken into account?
8© Prof. Dr. J.-M. Graf von der Schulenburg
Patient organizations (people concerned) Evaluation of experiences
Health care provider(physicians, industry)
Evaluation of markets and science
Public organizations/benefactors
Evaluation of structures
![Page 9: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/9.jpg)
Rare Diseases are currently attracting insufficient attention in Germany
9© Prof. Dr. J.-M. Graf von der Schulenburg
Quelle: BMG-study 2009
![Page 10: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/10.jpg)
Which individual care factors are important for patients?
10© Prof. Dr. J.-M. Graf von der Schulenburg
High competence of medical care
Information about new treatment possibilities
Psychosocial care
…
Fast access to new drugs
Europe-wide treatment options
Close to residential
care
Source: BMG-study 2009
![Page 11: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/11.jpg)
Patients with Rare Diseases need a comprehensive and specialised care
Qualified health care providers (medical and non-medical) are necessary Only a few specialists University hospitals
Patients have a high and comprehensive demand for care The German health care system is separated into different sectors High ambulatory, inpatient and rehabilitative health care utilisation Professionals in different sectors of care and interdisciplinary
cooperation are necessary Trans-sectoral concepts of care are essential
11© Prof. Dr. J.-M. Graf von der Schulenburg
![Page 12: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/12.jpg)
…economically uninteresting:
12© Prof. Dr. J.-M. Graf von der Schulenburg
0 – 7years
8 – 13years
14 – 17years
18 – 24years
25 – 34years
35 Jahreand older
300
400
500
600
100
200
Costs of ambulatory treatment for Mucoviscidosis
Source: Mucoviscidosis-study 2007
Rare Diseases from health care providers point of view:
Reimbursement
Other costs
Physiotherapy, diet guidance
Diagnostic service
Laboratory checkup
Routine checkup
Additional costs of the institute
![Page 13: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/13.jpg)
Three questions
13© Prof. Dr. J.-M. Graf von der Schulenburg
What is the issue?
What do we know?
What has to be done?
![Page 14: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/14.jpg)
Recommendations of the study
1. Implementation of National and European Centres of Reference or Expertise
2. Development and implementation of Shared-Care Models
3. Augment the evidence of drugs in Off-Label-Use
4. Creating and using therapy guidelines / clinical pathways
5. Intensified European co-operation
6. Formation of a national coalition for Rare Diseases under clear objectives and with a firm time schedule
7. Development of a German National Plan for Rare Diseases
14© Prof. Dr. J.-M. Graf von der Schulenburg
![Page 15: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/15.jpg)
Development of recommendations and
realisation of them: A national action league for
people with Rare Diseases (NAMSE),
where the different perspectives of all relevant
stakeholders are considered
Aim/result: German National Plan for
people with Rare Diseases
Announcement: 8. March 2010
15© Prof. Dr. J.-M. Graf von der Schulenburg
![Page 16: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/16.jpg)
Aims of NAMSE
► Implement the recommendations of the Council of the EU► Concentrate the current initiatives in the field of Rare Diseases► Enable common, coordinated and targeted activities in the field of Rare
Diseases► Contributions for a German National Plan for people with Rare Diseases► Assist the establishment of national Reference or Expertise Centres► Encourage pilot projects and actions in the field of Rare Diseases
© Prof. Dr. J.-M. Graf von der Schulenburg 16
![Page 17: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/17.jpg)
Steering committee (SC)► Decisions and controlling board► Members from different stakeholders of the health care system
respectively point of view ► Decision-making about e.g.
• Basic goals• Spheres of activity• Creation and staffing of working groups
► Proving and evaluating results of the working groups► Adopt recommendations and the implementation of them► Meet bimonthly
Organisation
© Prof. Dr. J.-M. Graf von der Schulenburg 17
![Page 18: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/18.jpg)
Working groups► Provide functional and continual work► Will be attended by the responsible departments of the BMG, the BMBF
and the self-help alliance for Rare Diseases in Germany ACHSE e.V.► Staffing with experts and people concerned (according to the aim or
question of the working group)► Possibility to subdivide in the case of complex problems► Sum up all results in written form► Regularly reporting the steering committee► Meeting frequency as required
Organisation
© Prof. Dr. J.-M. Graf von der Schulenburg 18
![Page 19: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/19.jpg)
External office of BMG► Coordinating the activity of NAMSE (Communication centre)► Scientific, administrative and organizational support of NAMSE► Organisation of the conferences for the steering group as well as the
working groups► Public Relations in coordination with the steering group► Preparation of (pilot-)projects
Organisation
© Prof. Dr. J.-M. Graf von der Schulenburg 19
![Page 20: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/20.jpg)
Patient information/transfer of knowledge Diagnostics and therapy (including the development of guidelines) Health care as well as quality assurance National and European networks of Reference and Expertise Centres Research Other topics, created by the steering committee
Spheres of activity
© Prof. Dr. J.-M. Graf von der Schulenburg 20
![Page 21: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/21.jpg)
Timetable
Announcement of NAMSE► March 2010
Constituent meeting► Summer 2010
Finalisation German National Plan for Rare Diseases ► Year 2013
© Prof. Dr. J.-M. Graf von der Schulenburg 21
![Page 22: Session 2 graf_von_der_schulenburg](https://reader034.fdocuments.net/reader034/viewer/2022052619/555cad6bd8b42aad358b4f6d/html5/thumbnails/22.jpg)
Thank you for your attention!